<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750373</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0257</org_study_id>
    <nct_id>NCT00750373</nct_id>
  </id_info>
  <brief_title>Early Surgery Versus Conventional Treatment in Infective Endocarditis</brief_title>
  <acronym>EASE</acronym>
  <official_title>A Randomized Comparison of Early Surgery Versus Conventional Treatment Strategy in Patients With High Embolic Risk of Infective Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There have been no prospective clinical studies in infective endocarditis comparing early
      surgery with the conventional treatment strategy based on current guidelines. The purpose of
      this prospective randomized trial is to compare clinical outcomes of early surgery versus
      conventional treatment strategy in patients with high embolic risk of infective endocarditis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infective Endocarditis is still associated with high mortality (16-25%) and high incidence of
      embolic events (10-49%), and the optimal therapeutic strategy remains unclear. The benefit of
      surgery was particularly high in patients with abscess formation, periannular complications,
      and moderate to severe heart failure related to acute mitral or aortic regurgitation.
      Retrospective studies reported that valve surgery was associated with improved survival, but
      the benefit of early surgery has not been adequately studied due to inherent treatment biases
      and significant differences in baseline characteristics. Embolic indications for surgery are
      more controversial, and surgery is usually performed in cases of recurrent emboli and persist
      vegetations despite appropriate antibiotic treatment. The combined risk of early surgery and
      valve prosthesis needs to be balanced against the potential benefit of preventing embolism
      and improving survival. Risk-benefit balance changes recently to favor early surgery in
      patients with high embolic risk of endocarditis for the following reasons. Identification of
      patients with high risk of embolism becomes possible with the use of transesophageal
      echocardiography. Patients with vegetation length &gt; 10 mm on transesophageal echocardiography
      have a significantly higher risk of embolization. With advances in surgical technique, urgent
      surgery is feasible with low operative mortality, and the success rate of valve repair has
      been increased.

      To the best of our knowledge, there have been no prospective outcome studies comparing early
      surgery with the conventional treatment strategy based on current guidelines. The purpose of
      this multi-center, prospective, randomized trial is to compare clinical outcomes of early
      surgery versus conventional treatment strategy in patients with high embolic risks of
      infective endocarditis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With In-hospital Death or Clinical Embolic Events</measure>
    <time_frame>within 6 weeks from the randomization</time_frame>
    <description>The composite of in-hospital death and clinical embolic events confirmed by imaging studies: the acute onset of clinical symptoms or signs of embolism and the occurrences of new lesions, as confirmed by follow-up imaging studies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Death</measure>
    <time_frame>up to 6 month after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrences of Infective Endocarditis</measure>
    <time_frame>up to 6 months after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Embolic Events Including Symptomatic and Asymptomatic Embolization Documented by Imaging Studies</measure>
    <time_frame>up to 6 months after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission Due to Development of Congestive Heart Failure</measure>
    <time_frame>up to 6 months after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Endocarditis</condition>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional Treatment based on current guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early surgery within 48 hours of randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Valve surgery with removal of vegetations</intervention_name>
    <description>Early valve repair or replacement with removal of vegetations within 48 hours of randomization</description>
    <arm_group_label>Surgery</arm_group_label>
    <other_name>early surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed as infective endocarditis based on modified Duke criteria
             fulfilling both conditions:

               -  severe mitral or aortic regurgitation

               -  vegetation length &gt; 10 mm on mitral or aortic valve

        Exclusion Criteria:

          -  Patients with urgent and emergent indication of surgery based on current guidelines;
             aortic abscess, moderate to severe heart failure due to valvular regurgitation,
             periannular complications, fungal endocarditis

          -  Prosthetic valve endocarditis

          -  Patient without vegetations on echocardiography

          -  Patients with ischemic or hemorrhagic stroke within 2 weeks before the admission

          -  Patients referred from other hospitals more than 7 days after the appropriate
             antibiotic treatment of infective endocarditis

          -  Patients who were not candidates for surgery based on age &gt; 80 years and coexisting
             malignancies

          -  Patients who did not consent to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-Hyun Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <results_first_submitted>June 29, 2012</results_first_submitted>
  <results_first_submitted_qc>August 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2012</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Duk-Hyun Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Endocarditis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Endocarditis, Bacterial</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were eligible for enrollment if they were diagnosed as definite infective endocarditis and had both severe mitral or aortic valve disease and vegetation length &gt; 10 mm. Between September 2006 and March 2011, a total of 76 patients were enrolled at the Asan Medical Center (n=71) and Seoul National University Hospital (n=5) in Korea.</recruitment_details>
      <pre_assignment_details>The exclusion criteria were defined as patients with moderate to severe CHF; heart block; annular or aortic abscess; fungal endocarditis; and those who were not candidates for early surgery on the basis of age &gt; 80 years, coexisting major embolic stroke with a risk of hemorrhagic transformation and/or poor medical status.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Conventional</title>
          <description>Conventional Treatment based on current guidelines</description>
        </group>
        <group group_id="P2">
          <title>Surgery</title>
          <description>Early surgery within 48 hours of randomization</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional</title>
          <description>Conventional Treatment based on current guidelines</description>
        </group>
        <group group_id="B2">
          <title>Surgery</title>
          <description>Early surgery within 48 hours of randomization</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="17"/>
                    <measurement group_id="B2" value="46" spread="15"/>
                    <measurement group_id="B3" value="47" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With In-hospital Death or Clinical Embolic Events</title>
        <description>The composite of in-hospital death and clinical embolic events confirmed by imaging studies: the acute onset of clinical symptoms or signs of embolism and the occurrences of new lesions, as confirmed by follow-up imaging studies.</description>
        <time_frame>within 6 weeks from the randomization</time_frame>
        <population>intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional</title>
            <description>Conventional Treatment based on current guidelines</description>
          </group>
          <group group_id="O2">
            <title>Surgery</title>
            <description>Early surgery within 48 hours of randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With In-hospital Death or Clinical Embolic Events</title>
          <description>The composite of in-hospital death and clinical embolic events confirmed by imaging studies: the acute onset of clinical symptoms or signs of embolism and the occurrences of new lesions, as confirmed by follow-up imaging studies.</description>
          <population>intention to treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We estimated that a sample size of 74 patients would provide 80% power to detect a significant difference with respect to the primary end point at the 2-sided significance level of 0.05, assuming that the in-hospital event rate would be 23% in the conventional treatment group and 3% in the early surgery group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Death</title>
        <time_frame>up to 6 month after enrollment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrences of Infective Endocarditis</title>
        <time_frame>up to 6 months after enrollment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Embolic Events Including Symptomatic and Asymptomatic Embolization Documented by Imaging Studies</title>
        <time_frame>up to 6 months after enrollment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Readmission Due to Development of Congestive Heart Failure</title>
        <time_frame>up to 6 months after enrollment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All patients underwent complete follow-up that began in September 2006 and ended in September 2011.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Conventional</title>
          <description>Conventional Treatment based on current guidelines</description>
        </group>
        <group group_id="E2">
          <title>Surgery</title>
          <description>Early surgery within 48 hours of randomization</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>In-hospital noncardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>embolism</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>recurrence of infective endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The EASE trial was a limited study in scope, in that it included patients with severe valvular disease and large vegetations, and excluded those with major stroke, prosthetic valve endocarditis or aortic abscess.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Duk-Hyun Kang</name_or_title>
      <organization>Asan Medical Center</organization>
      <phone>82-2-3010-3149</phone>
      <email>dhkang@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

